Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://excelchamps.com
Are you over 18 and want to see adult content?
A complete backup of https://goodweave.org
Are you over 18 and want to see adult content?
A complete backup of https://divisionsbc.ca
Are you over 18 and want to see adult content?
A complete backup of https://fossilera.com
Are you over 18 and want to see adult content?
A complete backup of https://evastore.jp
Are you over 18 and want to see adult content?
A complete backup of https://onpage.com
Are you over 18 and want to see adult content?
A complete backup of https://matthiasmedia.com
Are you over 18 and want to see adult content?
A complete backup of https://coolblades.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://bestonlinesportsbooks.info
Are you over 18 and want to see adult content?
A complete backup of https://vash-pc.ru
Are you over 18 and want to see adult content?
A complete backup of https://zoobrno.cz
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of hotcakesdesign.com
Are you over 18 and want to see adult content?
A complete backup of jardinesdelosperales.com
Are you over 18 and want to see adult content?
A complete backup of farmaciasloshidalgos.com.do
Are you over 18 and want to see adult content?
A complete backup of iconsunmi.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of ebooksfileserveidownload.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of crystalsandjewelry.com
Are you over 18 and want to see adult content?
A complete backup of buildquizzes.com
Are you over 18 and want to see adult content?
Text
PRESS RELEASES
Toronto, Ontario – September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder. CAREERS | DEEP GENOMICS Deep Genomics is located in the heart of Toronto. Toronto is the fastest growing tech hub in North America and widely recognized as one of the most livable cities in the world. Our facilities span experimental biology and computational analysis. We are located in the MaRS tower, right beside the University of Toronto, four researchhospitals
AI WORKBENCH
Our AI Workbench 1.0 focused on correcting RNA splicing as a means to restore protein expression. We recognized that a wide range of disorders, such as haploinsufficiencies can be potentially treated by boosting gene expression. Version 2.0 of the workbench was expanded to include seven mechanisms to increase expression and reduce the work MEDIA | DEEP GENOMICS Deep Genomics nabs $40M round, doubles down on AI and Wilson disease work. Canadian drug development company Deep Genomics has got off a $40 million series B round as it looks to double down on its rare genetic disease and artificial intelligence work. CONTACT | DEEP GENOMICS Corporate Headquarters: MaRS Centre, 661 University Ave, Suite 480 Toronto, Ontario, Canada, M5G 1M1 +1 647-598-8879. Business Development. Matt Cahill, Amanda Kay bd@deepgenomics.com. Press Inquiries. Megan Murphy press@deepgenomics.com PIPELINE | DEEP GENOMICS Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront. DEEP GENOMICS APPOINTS JEFFREY M. BROWN, PH.D., VICE TORONTO – May 3, 2021. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, PreclinicalResearch.
WILSON DISEASE
Why are we working on Wilson Disease. Deep Genomics is a biotechnology company that builds proprietary artificial intelligence (AI) technology and uses it to discover new ways to correct the effects of genetic mutations and develop personalized therapies for individualswith rare disease.
HOME | DEEP GENOMICSAI WORKBENCHUPDATESPIPELINECOMPANYPRESSCAREERS Finding therapies requires mining RNA biology data. But, this data is vast, complex and overwhelming, making standard approaches to drug discovery too slow and costly. Deep Genomics has the solution: Our AI Workbench untangles the complexity in RNA biology, identifies novel targets, and evaluates thousands of possibilities to identify the best COMPANY | DEEP GENOMICSCONTACTPRESSUPDATES Daniele Merico is the Head of Target Identification and interim Co-Director of Preclinical Research at Deep Genomics. Since the company started developing therapeutic oligonucleotides in 2017, he has led the identification of genetically-defined disorders targetablePRESS RELEASES
Toronto, Ontario – September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder. CAREERS | DEEP GENOMICS Deep Genomics is located in the heart of Toronto. Toronto is the fastest growing tech hub in North America and widely recognized as one of the most livable cities in the world. Our facilities span experimental biology and computational analysis. We are located in the MaRS tower, right beside the University of Toronto, four researchhospitals
AI WORKBENCH
Our AI Workbench 1.0 focused on correcting RNA splicing as a means to restore protein expression. We recognized that a wide range of disorders, such as haploinsufficiencies can be potentially treated by boosting gene expression. Version 2.0 of the workbench was expanded to include seven mechanisms to increase expression and reduce the work MEDIA | DEEP GENOMICS Deep Genomics nabs $40M round, doubles down on AI and Wilson disease work. Canadian drug development company Deep Genomics has got off a $40 million series B round as it looks to double down on its rare genetic disease and artificial intelligence work. CONTACT | DEEP GENOMICS Corporate Headquarters: MaRS Centre, 661 University Ave, Suite 480 Toronto, Ontario, Canada, M5G 1M1 +1 647-598-8879. Business Development. Matt Cahill, Amanda Kay bd@deepgenomics.com. Press Inquiries. Megan Murphy press@deepgenomics.com PIPELINE | DEEP GENOMICS Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront. DEEP GENOMICS APPOINTS JEFFREY M. BROWN, PH.D., VICE TORONTO – May 3, 2021. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, PreclinicalResearch.
WILSON DISEASE
Why are we working on Wilson Disease. Deep Genomics is a biotechnology company that builds proprietary artificial intelligence (AI) technology and uses it to discover new ways to correct the effects of genetic mutations and develop personalized therapies for individualswith rare disease.
PUBLICATIONS
Publications. Our scientists regularly publish in their fields' most influential peer-reviewed journals. Here is a selection of ourcontributions.
EVENTS | DEEP GENOMICS Events and Presentations. March 13, 2021. December 4, 2020 A genetic medicine for Wilson disease. Brendan Frey, CEO, Deep Genomics. Wilson Disease Association Virtual Conference. September 28, 2020 Fireside chat on discovering therapies using AI. BrendanPROJECT SATURN
Our's is the world's first drug design system built around a molecular biology AI. In Project Saturn, we're using our platform to evaluate over 69 billion oligonucleotide molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended.Think of it as a toolkit for controlling cell biology along DEEP GENOMICS RAISES $40 MILLION IN SERIES B FINANCING TORONTO – January 7, 2020. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 million in new investment. The proceeds from this financing will be used to develop new treatments for rare genetic diseases, and to expand the company’s proprietary AIdiscovery
PRESS RELEASES
TORONTO, Ontario, Canada – June 18, 2019. Deep Genomics, the leading AI therapeutics company, announced today that the output of its discovery pipeline has quadrupled in the past year and that it has appointed Johan Fransson, Ph.D. as Head of Preclinical Research, effective immediately. MEDIA | DEEP GENOMICS As any high school biology student knows, genes come in pairs. When Brendan Frey recounts the origins of Deep Genomics - the Toronto AI startup he co-founded - he likewise tells a pair of stories, one intimate and tragic, the other immense and world-changing. DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI Deep Genomics Nominates Industry’s First AI-Discovered Therapeutic Candidate. Toronto, Ontario – September 25, 2019. Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate forCOMPANY_OLD
Brendan Frey is a Toronto-based entrepreneur, engineer and scientist.He founded Deep Genomics in 2015, to address the need for an AI-driven approach to developing genetic medicines. He is responsible for the creation of the AI technology, processes and culture that enable the team to advance drug programs rapidly and with a high success rate, and for the discovery, development, partnering and TAKING ON METABOLIC & NEURODEGENERATIVE DISORDERS TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the leading AI therapeutics company that has built a platform using machine learning, genomics, cell biology and automation, today announced they are investing $10 million to expand their preclinical platform and to develop therapies for metabolic and neurodegenerative disorders.“For
WHAT INFORMATION PATIENT TESTING PROGRAM FOR WILL BE Wilson Disease Wilson disease (WD) is a genetic condition in which excess copper builds up in the body. The condition results from a change (mutation) in HOME | DEEP GENOMICSAI WORKBENCHUPDATESPIPELINECOMPANYPRESSCAREERS Our proprietary AI Workbench is designed for data-driven prediction, positive feedback loops, and exponential growth. It enables us to identify leads for over 50% of COMPANY | DEEP GENOMICSCONTACTPRESSUPDATES Daniele Merico is the Head of Target Identification and interim Co-Director of Preclinical Research at Deep Genomics. Since the company started developing therapeutic oligonucleotides in 2017, he has led the identification of genetically-defined disorders targetablePRESS RELEASES
Toronto, Ontario – September 25, 2019.Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder. CAREERS | DEEP GENOMICS Deep Genomics is located in the heart of Toronto. Toronto is the fastest growing tech hub in North America and widely recognized as one of the most livable cities in the world. CONTACT | DEEP GENOMICS Corporate Headquarters: MaRS Centre, 661 University Ave, Suite 480 Toronto, Ontario, Canada, M5G 1M1 +1 647-598-8879. Business Development. Matt Cahill, Amanda Kay bd@deepgenomics.com. Press Inquiries. Megan Murphy press@deepgenomics.com PIPELINE | DEEP GENOMICS Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.AI WORKBENCH
Our AI Workbench enables us to efficiently find drug candidates with desirable properties. We are focusing on the development and marketing of steric blocking oligonucleotides (SBOs) that target the genetic determinants of disease at the level of RNA or DNA. MEDIA | DEEP GENOMICS Brendan Frey set out, when he began the project to pick out a lead program for Deep Genomics, to prove that the artificial intelligence systems his lab has designed can identify new drug targets and find a winning candidate much faster than traditional methods.PROJECT SATURN
Our's is the world's first drug design system built around a molecular biology AI. In Project Saturn, we're using our platform to evaluate over 69 billion oligonucleotide molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended.Think of it as a toolkit for controlling cell biology alongWILSON DISEASE
Why are we working on Wilson Disease. Deep Genomics is a biotechnology company that builds proprietary artificial intelligence (AI) technology and uses it to discover new ways to correct the effects of genetic mutations and develop personalized therapies for individualswith rare disease.
HOME | DEEP GENOMICSAI WORKBENCHUPDATESPIPELINECOMPANYPRESSCAREERS Our proprietary AI Workbench is designed for data-driven prediction, positive feedback loops, and exponential growth. It enables us to identify leads for over 50% of COMPANY | DEEP GENOMICSCONTACTPRESSUPDATES Daniele Merico is the Head of Target Identification and interim Co-Director of Preclinical Research at Deep Genomics. Since the company started developing therapeutic oligonucleotides in 2017, he has led the identification of genetically-defined disorders targetablePRESS RELEASES
Toronto, Ontario – September 25, 2019.Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder. CAREERS | DEEP GENOMICS Deep Genomics is located in the heart of Toronto. Toronto is the fastest growing tech hub in North America and widely recognized as one of the most livable cities in the world. CONTACT | DEEP GENOMICS Corporate Headquarters: MaRS Centre, 661 University Ave, Suite 480 Toronto, Ontario, Canada, M5G 1M1 +1 647-598-8879. Business Development. Matt Cahill, Amanda Kay bd@deepgenomics.com. Press Inquiries. Megan Murphy press@deepgenomics.com PIPELINE | DEEP GENOMICS Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.AI WORKBENCH
Our AI Workbench enables us to efficiently find drug candidates with desirable properties. We are focusing on the development and marketing of steric blocking oligonucleotides (SBOs) that target the genetic determinants of disease at the level of RNA or DNA. MEDIA | DEEP GENOMICS Brendan Frey set out, when he began the project to pick out a lead program for Deep Genomics, to prove that the artificial intelligence systems his lab has designed can identify new drug targets and find a winning candidate much faster than traditional methods.PROJECT SATURN
Our's is the world's first drug design system built around a molecular biology AI. In Project Saturn, we're using our platform to evaluate over 69 billion oligonucleotide molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended.Think of it as a toolkit for controlling cell biology alongWILSON DISEASE
Why are we working on Wilson Disease. Deep Genomics is a biotechnology company that builds proprietary artificial intelligence (AI) technology and uses it to discover new ways to correct the effects of genetic mutations and develop personalized therapies for individualswith rare disease.
PUBLICATIONS
Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront. EVENTS | DEEP GENOMICS Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.AI WORKBENCH
Our AI Workbench enables us to efficiently find drug candidates with desirable properties. We are focusing on the development and marketing of steric blocking oligonucleotides (SBOs) that target the genetic determinants of disease at the level of RNA or DNA.PROJECT SATURN
Our's is the world's first drug design system built around a molecular biology AI. In Project Saturn, we're using our platform to evaluate over 69 billion oligonucleotide molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended.Think of it as a toolkit for controlling cell biology alongPRESS RELEASES
With frustration fresh on his mind, Frey knew he wanted to work on genomics. Out of hardship, Frey sought a way to make a positive impact, and his deep learning background would be his secret weapon. DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI Toronto, Ontario – September 25, 2019.Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder. MEDIA | DEEP GENOMICS As any high school biology student knows, genes come in pairs. When Brendan Frey recounts the origins of Deep Genomics - the Toronto AI startup he co-founded - he likewise tells a pair of stories, one intimate and tragic, the other immense and world-changing. TAKING ON METABOLIC & NEURODEGENERATIVE DISORDERS For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders. DISCOVERING THERAPIES FOR NEUROMUSCULAR DISORDERS CAMBRIDGE, Mass. U.S.A. and TORONTO, Ontario, Canada, April 10, 2018- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., the leading AI therapeutics company that is building a new universe of genetic medicines using its machine learning-driven biomedical WHAT INFORMATION PATIENT TESTING PROGRAM FOR WILL BE Wilson Disease Wilson disease (WD) is a genetic condition in which excess copper builds up in the body. The condition results from a change (mutation) in* AI Workbench
* Updates
* Pipeline
* Company
* Press
* Careers
* Contact
* AI Workbench
* Updates
* Pipeline
* Company
* Press
* Careers
* Contact
*
Creating A New Universe OfGenetic Medicines
Revolutions in AI, biology and automation are enabling a new approach to drug development. Deep Genomics is at the forefront. AI-POWERED DISCOVERY PLATFORM THE FUTURE OF DRUG DEVELOPMENT WILL RELY ON ARTIFICIAL INTELLIGENCE, BECAUSE BIOLOGY IS TOO COMPLEX FOR HUMANS TO UNDERSTAND Our AI platform rapidly directs us to the best drug candidates. It knows biology, from disease biomarkers all the way down to the level of DNA, RNA and the molecular machinery of the cell. Everyone at Deep Genomics uses the platform to do their work, and everyone participates in improving the platform. That includes our geneticists, biologists, chemists, toxicologists, clinicians and drug developers. Now, we’re creating and clinically evaluating new oligonucleotide therapies, designed up front to be effective and safe.Learn More
PROJECT SATURN
SMART DRUG DESIGN IS ABOUT PREDICTING OUTCOMES UP FRONT. THAT'S WHAT OUR AI PLATFORM DOES BEST, AND SATURN IS THE PROOF In Project Saturn, we're using our platform to evaluate over 69 billion molecules against 1 million targets, _in silico_, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended. Think of it as a toolkit for controlling cell biology along crucial pathways, rapidly unlocking therapies with greater potential.Learn More
PRESS
“Deep Genomics, founded in 2015, is at the forefront of efforts by big companies, startups and ...”October 19, 2018
“For the first time in history, our ability to collect data on our biology has outpaced our ability to...”April 1, 2019
“The basic fact is no human or group of humans will ever understand how the genome works”August 28, 2017
“The next blockbuster drug could be developed with help from machine learning techniques”May 3, 2017
See all coverage
JOIN US
We are looking for individuals who are inspired to join us in building a new kind of world-class genetic medicine company.Learn More
UPDATES
Learn about the latest developments at Deep Genomics DEEP GENOMICS RAISES $40 MILLION IN SERIES B FINANCINGJanuary 7, 2020
DEEP GENOMICS NOMINATES INDUSTRY'S FIRST AI - DISCOVERED THERAPEUTICCANDIDATE
September 25, 2019
Artificial Intelligence enables target and drug candidate to be identified in less than 18 months. Initial target of Wilson disease represents significant clinical need, new era of drug discovery. DEEP GENOMICS PLANS FOR CLINICAL INNOVATION, APPOINTS PETER BARTON HUTT AS STRATEGIC ADVISORJune 25, 2019
Deep Genomics is proud to announce that Peter Barton Hutt, Senior Counsel at Covington & Burling and former Chief Counsel of the U.S. Food and Drug Administration, has joined the company as aStrategic Advisor.
See All Updates
FIND US
MaRS Centre, 661 University Avenue, Suite 480 Toronto, Ontario, Canada, M5G 1M1FOLLOW US
*
*
CONTACT US
Megan Murphy
contact@deepgenomics.com 2020 DEEP GENOMICS. ALL RIGHTS RESERVED.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0